HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology4528 papers

Alzheimer's disease

Last edited: 4/23/2026

Overview

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and the accumulation of amyloid-β plaques and tau tangles in the brain 1 2 3 4.

Diagnosis

Clinical Criteria: Cognitive impairment affecting daily life, gradual onset, and progressive worsening 28 30.

Biomarkers:

- CSF Biomarkers: Elevated levels of phosphorylated tau (p-tau217) and decreased amyloid-β42 1 29. - Blood Biomarkers: Emerging use of plasma p-tau217 for screening 1 29.

Imaging: Amyloid PET scans showing amyloid deposition, MRI for hippocampal atrophy 35 50.

Neuropsychological Testing: Standardized assessments to evaluate cognitive domains 28 34.

Management

First-Line Treatments:

- Acetylcholinesterase Inhibitors: Donepezil, rivastigmine, galantamine 8 33. - Memantine: For moderate to severe AD, used in combination with cholinesterase inhibitors 33.

Adjunctive Therapies:

- Anti-Amyloid Therapies: Lecanemab (aduhelm) for early AD, with close monitoring for amyloid-related imaging abnormalities (ARIA) 33 40 44 53. - Lifestyle Modifications: Cognitive stimulation, physical exercise, and management of cardiovascular risk factors 7 37 65.

Special Populations

Elderly: Focus on comprehensive management including cardiovascular risk reduction 6 22 65.

Comorbidities: Hypertension management with ACE inhibitors or ARBs may preserve cognitive function 6 65.

Polypharmacy: Monitor for sex-specific effects on AD pathology and metabolomic profiles 45 46.

Key Recommendations

Utilize plasma p-tau217 as a blood biomarker for suspected AD in specialized care settings (Evidence: Moderate) 29.

Implement anti-amyloid therapies like lecanemab cautiously, with vigilant monitoring for ARIA and adverse events (Evidence: Moderate) 40 53.

Prioritize cardiovascular risk factor management, including hypertension control, to potentially mitigate cognitive decline (Evidence: Moderate) 6 65.

Consider cognitive and physical exercise programs tailored to the elderly population to support cognitive function (Evidence: Moderate) 7 37.

Evaluate polypharmacy impacts carefully, especially in older adults with AD, considering sex-specific effects (Evidence: Weak) 45 46.

References

Showing 100 most recent of 1023 indexed papers.

1 Smith JE. Scientists brace for expansion of Alzheimer's blood tests. Science (New York, N.Y.) 2026. link 2 Piller C. Fake data from trial sites ruin studies, drug firms say. Science (New York, N.Y.) 2026. link 3 Stephan AT, Martinez V, Moss D, Walton A, Bonetto J, Hertzfeld A et al.. Undergraduate students engaging in hands-on gerontology research: A participatory case study of value gained and lessons learned. Gerontology & geriatrics education 2026. link 4 Thacker A, Parks AL, Dohan D, Ramirez Gomez LA, Ritchie CS, Shah SJ et al.. A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers. Journal of Alzheimer's disease : JAD 2026. link 5 Murali KP, Hua M, Stone PW, Dick A, Gracner T. State POLST Program Maturity Status and Dying in the Nursing Home or Hospice in the United States: An Event Time Study. Journal of the American Medical Directors Association 2026. link 6 Bax F, Oltmer J, Auger CA, Bonkhoff A, Coughlan GT, Melloni A et al.. APOE-mediated sex differences in microvascular pathology and AD-associated proteinopathies in the medial temporal lobe. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026. link 7 Ferré-González L, Peña-Bautista C, Álvarez-Sánchez L, Peretó M, García-Vallés L, Raga L et al.. Plasma lipidomics in women with Alzheimer's disease: Exploring associations with ApoE genotype and cardiovascular risk. Journal of clinical lipidology 2026. link 8 Li Y, Li X, Ren J, Hong H, Sun J, Ma L et al.. Lumacaftor and fexofenadine prevent donepezil-induced LQTS via PHE656-mediated hERG chaperoning. Biochemical pharmacology 2026. link 9 Hendrickx Van de Craen E, Bossaerts L, Sieben A, Van den Bossche T, Bjerke M, Hanseeuw B et al.. Rare ABCA7 mutations in Alzheimer's disease and cerebral amyloid angiopathy pathology. Neurobiology of aging 2026. link 10 Reyes H, Mondragon J, Frank C, Murphy C. Examining functional connectivity in metabolic syndrome and small vessel disease: A novel approach to understanding olfactory dysfunction and Alzheimer's disease. Brain research 2026. link 11 Yedor LM, Chambers KO, Moran-Garrido M, Perfetto S, Lin WZ, Ryoo SW et al.. Serum long-chain omega-3 and omega-6 fatty acids differentially predict brain atrophy, white matter hyperintensities, and lacunes in individuals with cerebral small vessel disease with or without Alzheimer's disease. Journal of Alzheimer's disease : JAD 2026. link 12 Kanwal A, Kerman BE, Wang S, Camey K, Li B, Flores-Aguilar L et al.. A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026. link 13 Elia A, Parodi-Rullan R, Vazquez-Torres R, Carey A, Zhao H, Javadov S et al.. Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 14 Khan S, Imam A, Singh S, Ahmed A, Hassan MI, Shahid M et al.. Exploring the intersection of Alzheimer's disease and comorbidities: a review of the interplay between multiple chronic conditions. Biochimica et biophysica acta. Molecular basis of disease 2026. link 15 Marcolini S, Mondragón JD, van Roon AM, Tegegne BS, Riese H, Vliegenthart R et al.. Limited evidence for heart rate variability as a predictor of cognitive and pathophysiological brain markers. Journal of Alzheimer's disease : JAD 2026. link 16 Anwer M, Poliakova T, Albanus RD, Bhuiyan MIH, Brickman AM, Chaudhuri S et al.. Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory. Mammalian genome : official journal of the International Mammalian Genome Society 2026. link 17 Loftus JR, McClelland AC, Hsu K, Nayak GK, Bruno M, Jachung R et al.. Accelerated MRI Sequences for Intracranial Hemorrhage Screening. Investigative radiology 2026. link 18 Bahrani AA, Nelson PT, Abner EL, Powell DK, Norris CM, Coskun EP et al.. White matter hyperintensity regression: Fact or artifact?. Neurobiology of aging 2026. link 19 Wang J, Zhang Y, Wu H, Yu S, Cai X, Zhang Y et al.. Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling. Chinese journal of natural medicines 2026. link61109-0) 20 An B, Auger SA, Lutsey PL, Mielke MM, Yu F, Hoogeveen RC et al.. Association of LDL cargo proteins with white matter hyperintensity volume in older adults from the atherosclerosis risk in communities study. Journal of Alzheimer's disease : JAD 2026. link 21 Fastenau C, Crisp R, Keating M, Ochoa E, Richardson TE, Flanagan ME et al.. Sialylation patterns in cerebral amyloid angiopathy. Brain pathology (Zurich, Switzerland) 2026. link 22 Jiang E, Ullah S, Waheed I, Han J, Zhang X. Hypertension as a Major Risk Factor in Alzheimer's Disease: Mechanisms, Interactions and Therapeutic Perspectives. Clinical interventions in aging 2026. link 23 Jafari EA, Alshahawey M, Zaman MA, Smith SM, Gong Y, Smith GE et al.. Characterizing Alzheimer's Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record-Based Data. Clinical pharmacology and therapeutics 2026. link 24 Xiong W, Luo Z, Wang H, Su Q, Wang H, Xu J et al.. Amyloid beta 42 disrupts cardiac function in Alzheimer's disease mice via SLC31A1 upregulation-mediated cuproptosis. Basic research in cardiology 2026. link 25 Yang D, Wei R, Zhu J, Chen J, Wang S, Cai H et al.. Class-Specific Antihypertensives and Alzheimer's Disease: Genotype- and Hypertension-Stratified Analysis. Molecular neurobiology 2026. link 26 Parker S, James AF, Mastitskaya S. The causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic review. The Journal of physiology 2026. link 27 Ziegler KC, Askarova A, Gergian C, Yaa RM, van Dalen JD, Transfeld JL et al.. The brain neurovascular epigenome and its association with dementia. Neuron 2026. link 28 Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ et al.. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 29 Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK et al.. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 30 Dickerson BC, Atri A, Clevenger C, Karlawish J, Knopman D, Lin PJ et al.. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 31 Suárez-Calvet M, Abdelnour C, Alcolea D, Mendióroz-Iriarte M, Balasa M, Morenas-Rodríguez E et al.. Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia 2025. link 32 Bettcher BM, Gunn-Sandell LB, Lopez-Esquibel N, Carlson NE, Krupa JR, Lum HD et al.. Integrating home-based video teleneuropsychology into neurology clinical practice: Utility in patients with suspected typical or atypical Alzheimer's disease presentations. The Clinical neuropsychologist 2025. link 33 Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N. Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis. Ageing research reviews 2025. link 34 Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ et al.. The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 35 Kakeda S, Miki Y, Kudo K, Mori H, Tokumaru AM, Abe O et al.. Practical brain MRI guidelines for anti-Aβ antibody treatment in early symptomatic Alzheimer's disease. Japanese journal of radiology 2025. link 36 Han GZ, Liang ZH, Guo LY, Liu MM. Trends in the Prevalence and Development of Alzheimer's Disease Among the Elderly Chinese Population: A Systematic Review. Revista de neurologia 2025. link 37 Sui S, Wang M. Optimizing exercise dosage for executive function in alzheimer's disease: A Bayesian dose-response meta-analysis of randomized trials. Archives of gerontology and geriatrics 2025. link 38 Abdelwahab SI, Taha MME, Farasani A, Abdullah SM, Moshi JM, Alshahrani AF et al.. Bibliometric analysis: A few suggestions (Part Two). Current problems in cardiology 2025. link 39 Wrigley S, Huynh ALH, Amadoru S, Zeimer H, Tan I, Woodward M et al.. Monoclonal Antibody Therapies in Alzheimer's Disease: A Guide for Emergency Physicians. Emergency medicine Australasia : EMA 2025. link 40 Rech MA, Carpenter CR, Aggarwal NT, Hwang U. Anti-Amyloid Therapies for Alzheimer's Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician. Annals of emergency medicine 2025. link 41 Harden JT, Heyn PC, Hill CV, Oh ES, Perez GA. Increasing Representation/Inclusivity of Older Adults and Investigators From Minoritized Groups in Aging Research. The Gerontologist 2025. link 42 Casten R, Kelley M, Lawal H, Lopez BL, Parks S, Perchiniak E et al.. Inspiring Undergraduate Student Training in Alzheimer's Research (USTAR): Training the Next Generation of Aging Scientists. Journal of the American Geriatrics Society 2025. link 43 Austin ME, Ingram LA, McCollum Q, Levkoff SE, Friedman DB. A dual approach to addressing gaps in scholar diversity in aging research. Gerontology & geriatrics education 2025. link 44 Shen B, Zhang Y, Travison TG, Shardell M, McCoy RG, Saegusa T et al.. A joint learning framework for analyzing data from national geriatric centralized networks: A new toolbox deciphering real-world complexity. Journal of biomedical informatics 2025. link 45 Eroli F, Johnell K, Acararicin Z, Tsagkogianni C, Zerial S, Lancia S et al.. Commonly prescribed multi-medication therapies exert sex-specific effects on Alzheimer's disease pathology and metabolomic profiles in App. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 46 Coates MC, McClure LA, Vader D, Finley M, Sefcik JS, Gitlin LN et al.. Impact of Polypharmacy on Symptoms and Health Outcomes in Older Adults With and Without Alzheimer's Disease and Related Dementias. Biological research for nursing 2025. link 47 Alghamdi A, de Vos S, Bos JH, Schuiling-Veninga CC, van Munster BC, Mubarik S et al.. A matched case-control study on polypharmacy and co-medications one year before drug treatment for Alzheimer's disease. Journal of Alzheimer's disease : JAD 2025. link 48 Humblet-Baron S, Feng Y, Veiga R, Neumann J, Prezzemolo T, Pasciuto E et al.. A systems immunology analysis of Alzheimer's disease reveals an age- and environmental exposure-independent disturbance in B cell maturation. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025. link 49 Lee C, Park J, Fain M, Galvin JE, Park L, Ahn H. Immediate and long-term effects of transcranial direct current stimulation on pain relief in older adults with Alzheimer's disease and related dementias: A pilot study. Geriatric nursing (New York, N.Y.) 2025. link 50 Marwaha S, Agarwal R, Tripathi M, Tripathi S. Unlocking the Vitamin Puzzle: Investigating Levels in People With Alzheimer's Disease Versus Healthy Controls Through Systematic Review and Network Meta-Analysis. Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 2025. link 51 Han W, Morris R, Bu K, Zhu T, Huang H, Cheng F. Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database. Canadian journal of physiology and pharmacology 2025. link 52 Ji H, Zhao Z, Zhao C. Unveiling Aducanumab's safety profile: A comprehensive pharmacovigilance analysis. PloS one 2025. link 53 Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X et al.. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. Alzheimer's research & therapy 2025. link 54 Li J, Zhang F, Eisel UL. Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system. Journal of Alzheimer's disease : JAD 2025. link 55 Ge W, Yan Y, Hu Y, Lin S, Mao P. Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data. Journal of Alzheimer's disease : JAD 2025. link 56 Zhou J, Wei Z, Huang W, Liu M, Wu X. Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer's Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System. The Annals of pharmacotherapy 2025. link 57 Pluta R, Ułamek-Kozioł M, Kocki J, Bogucka-Kocka A, Bogucki J, Czuczwar SJ. Alterations of Apolipoprotein A1, E, and J Genes in the Frontal Cortex in an Ischemic Model of Alzheimer's Disease with 2-Year Survival. International journal of molecular sciences 2025. link 58 Kim TA, Cruz G, Syty MD, Wang F, Wang X, Duan A et al.. Neural circuit mechanisms underlying aberrantly prolonged functional hyperemia in young Alzheimer's disease mice. Molecular psychiatry 2025. link 59 Wrigley S, Cody R, Amadoru S, Huynh A, Galante O, Mandrawa C et al.. Prevalence and associations of cerebral microbleeds in an Australian Memory clinic cohort. Internal medicine journal 2025. link 60 Gheni G, Shinohara M, Masuda-Suzukake M, Shindo A, Watanabe A, Kawai K et al.. Cerebral hypoperfusion reduces tau accumulation. Annals of clinical and translational neurology 2025. link 61 Cheng Y, Lin L, Huang P, Zhang J, Wang Y, Pan X. Hypotension with neurovascular changes and cognitive dysfunction: An epidemiological, pathobiological, and treatment review. Chinese medical journal 2025. link 62 Liu C, Liu J, Wang YY, Xu SF, Yu LM. APOE Lipoprotein Particles: Pathophysiology, Therapy, and the Crosstalk in Alzheimer's Disease and Cardiovascular Disease. Molecular neurobiology 2025. link 63 Huang W, Zeng R, Li Y, Hua Y, Liu L, Chen M et al.. Identification of Alzheimer's disease and vascular dementia based on a Deep Forest and near-infrared spectroscopy analysis method. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2025. link 64 Wei X, Li L, Zhao G, Luan Y, Wang Q, Ning W. Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management. Clinical and experimental hypertension (New York, N.Y. : 1993) 2025. link 65 Yasmin S, Ashique S, Taj T, Garg A, Das J, Shorog E et al.. The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update. Brain research 2025. link 66 Marzban S, Dastgheib Z, Lithgow B, Moussavi Z. Using principal component analysis to determine which vestibular stimuli provide best biomarkers for separating Alzheimer's from mixed Alzheimer's disease. Medical & biological engineering & computing 2025. link 67 Parvin F, Larsson JNK, Jackson WS, Nyström S, Hammarström P. Efficient Seeding of Cerebral Vascular Aβ-Amyloidosis by Recombinant AβM1-42 Amyloid Fibrils. Journal of molecular biology 2025. link 68 Yang Q, Yang C, Lv H, Zheng X, Mao S, Liu N et al.. Autophagy Regulation Attenuates Neuroinflammation and Cognitive Decline in an Alzheimer's Disease Mouse Model with Chronic Cerebral Hypoperfusion. Inflammation 2025. link 69 Pluta R, Kocki J, Bogucki J, Bogucka-Kocka A, Czuczwar SJ. Apolipoprotein (. Journal of Alzheimer's disease : JAD 2025. link 70 Shearon J, Jackson J, Head D. Role of Cardiovascular Risk in Associations of Brain-Derived Neurotrophic Factor with Longitudinal Brain and Cognitive Trajectories in Older Adults. Experimental aging research 2025. link 71 Piccolino AL, Piccolino AR, Piccolino SG. Distinguishing Alzheimer's disease from other dementias using pattern profile analysis in the Meyers Neuropsychological Battery: An exploratory study. Applied neuropsychology. Adult 2025. link 72 Hernández-Fernández F, Martínez-Fernández I, Barbella-Aponte R, Vilar IF, Ayo-Martín O, García-García J et al.. Iatrogenic cerebral amyloid angiopathy and Alzheimer's disease co-pathology. Annals of clinical and translational neurology 2025. link 73 Reimers-Wessberg M, Xu H, Fastbom J, Seiger Å, Eriksdotter M. Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure. European heart journal. Cardiovascular pharmacotherapy 2025. link 74 Matsunaga M, Tanihara S, He Y, Yatsuya H, Ota A. Sex-specific association of comorbid heart failure on mortality after Alzheimer's disease diagnosis in older adults aged 75 years and above: A health insurance claims data analysis in Japan. Journal of Alzheimer's disease : JAD 2025. link 75 Ji Q, Chen J, Li Y, Tao E, Zhan Y. Incidence and prevalence of Alzheimer's disease in China: a systematic review and meta-analysis. European journal of epidemiology 2024. link 76 Nijakowski K, Owecki W, Jankowski J, Surdacka A. Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis. International journal of molecular sciences 2024. link 77 Terao I, Kodama W. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. Ageing research reviews 2024. link 78 Gao Y, Liu Y, Li Y. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2024. link 79 Xiang C, Zhang Y. Comparison of Cognitive Intervention Strategies for Individuals With Alzheimer's Disease: A Systematic Review and Network Meta-analysis. Neuropsychology review 2024. link 80 Avgerinos KI, Manolopoulos A, Ferrucci L, Kapogiannis D. Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. Scientific reports 2024. link 81 Terao I, Kodama W. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Journal of Alzheimer's disease : JAD 2024. link 82 Zhang X, Lv R, Sun Y, Liu TC. The safety and effectiveness of 40 Hz γ-tACS in Alzheimer's disease: A meta-analysis. Journal of Alzheimer's disease : JAD 2024. link 83 Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G. A Meta-Analysis on Presynaptic Changes in Alzheimer's Disease. Journal of Alzheimer's disease : JAD 2024. link 84 Cheng YW, Lin YJ, Lin YS, Hong WP, Kuan YC, Wu KY et al.. Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society. Journal of the Formosan Medical Association = Taiwan yi zhi 2024. link 85 Zheng X, Wang S, Huang J, Li C, Shang H. Predictors for survival in patients with Alzheimer's disease: a large comprehensive meta-analysis. Translational psychiatry 2024. link 86 García-Carlos CA, Basurto-Islas G, Perry G, Mondragón-Rodríguez S. Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-β and Phosphorylated Tau Proteins. Journal of Alzheimer's disease : JAD 2024. link 87 McLaughlin J, Scotton WJ, Ryan NS, Hardy JA, Shoai M. Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024. link 88 Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q. Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis. European neurology 2024. link 89 Baek AE. Lipid drops in on Alzheimer's disease. Science signaling 2024. link 90 Fessel J. Special Issue "Pathophysiology and Treatment of Alzheimer's Disease". International journal of molecular sciences 2024. link 91 Antimisiaris D. They Are Here: Anti-Amyloid Therapies to Treat Dementia. The Senior care pharmacist 2024. link 92 Couzin-Frankel J. Preprint on Alzheimer's drug deaths ignites author dispute. Science (New York, N.Y.) 2024. link 93 Couzin-Frankel J. Hunt for infectious causes of Alzheimer's gains momentum. Science (New York, N.Y.) 2024. link 94 Boccardi V, Ruggiero C, Cecchetti R, Mecocci P. Geroscience and the Fight Against Alzheimer's Disease: Between Myth and Reality. Journal of Alzheimer's disease : JAD 2024. link 95 Gerald MS, Major L. Intentional Strategic Changes in the National Institute on Aging's RCMAR Program: Broadening its Scope and Reach to Strengthen its Impact. The Gerontologist 2024. link 96 Thompson S, Trinidad D, Woo E, Edland S, Marquez B. Advancing Diversity in Aging and Alzheimer's Disease Research and Clinical Care: Lessons Learned from Educational and Career Trajectories of Recent Mentorship Program Graduates. International journal of aging & human development 2024. link 97 Guest MA, Clark-Shirley L, Hancock C, Newsham TMK, Nikzad-Terhune K, Jenkins K. An environmental scan of aging-related micro-credentials: Implications for gerontology and gerontologists. Gerontology & geriatrics education 2024. link 98 Badin L, Bailly N, Pennequin V. Implementation of equine-assisted intervention for older adults with Alzheimer's disease residing in a nursing home: Brakes and levers. International journal of older people nursing 2024. link 99 Abadir P, Oh E, Chellappa R, Choudhry N, Demiris G, Ganesan D et al.. Artificial Intelligence and Technology Collaboratories: Innovating aging research and Alzheimer's care. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024. link 100 Akkan Suzan A, Ozen Barut B. The relationship between polypharmacy and physical performance in patients with early-stage Alzheimer's disease. Current medical research and opinion 2024. link

Original source

[1]
Scientists brace for expansion of Alzheimer's blood tests. — Smith JE Science (New York, N.Y.) (2026)
[2]
Fake data from trial sites ruin studies, drug firms say. — Piller C Science (New York, N.Y.) (2026)
[3]
Undergraduate students engaging in hands-on gerontology research: A participatory case study of value gained and lessons learned. — Stephan AT, Martinez V, Moss D, Walton A, Bonetto J, Hertzfeld A et al. Gerontology & geriatrics education (2026)
[4]
A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers. — Thacker A, Parks AL, Dohan D, Ramirez Gomez LA, Ritchie CS, Shah SJ et al. Journal of Alzheimer's disease : JAD (2026)
[5]
State POLST Program Maturity Status and Dying in the Nursing Home or Hospice in the United States: An Event Time Study. — Murali KP, Hua M, Stone PW, Dick A, Gracner T Journal of the American Medical Directors Association (2026)
[6]
APOE-mediated sex differences in microvascular pathology and AD-associated proteinopathies in the medial temporal lobe. — Bax F, Oltmer J, Auger CA, Bonkhoff A, Coughlan GT, Melloni A et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2026)
[7]
Plasma lipidomics in women with Alzheimer's disease: Exploring associations with ApoE genotype and cardiovascular risk. — Ferré-González L, Peña-Bautista C, Álvarez-Sánchez L, Peretó M, García-Vallés L, Raga L et al. Journal of clinical lipidology (2026)
[8]
Lumacaftor and fexofenadine prevent donepezil-induced LQTS via PHE656-mediated hERG chaperoning. — Li Y, Li X, Ren J, Hong H, Sun J, Ma L et al. Biochemical pharmacology (2026)
[9]
Rare ABCA7 mutations in Alzheimer's disease and cerebral amyloid angiopathy pathology. — Hendrickx Van de Craen E, Bossaerts L, Sieben A, Van den Bossche T, Bjerke M, Hanseeuw B et al. Neurobiology of aging (2026)
[10]
Examining functional connectivity in metabolic syndrome and small vessel disease: A novel approach to understanding olfactory dysfunction and Alzheimer's disease. — Reyes H, Mondragon J, Frank C, Murphy C Brain research (2026)
[11]
Serum long-chain omega-3 and omega-6 fatty acids differentially predict brain atrophy, white matter hyperintensities, and lacunes in individuals with cerebral small vessel disease with or without Alzheimer's disease. — Yedor LM, Chambers KO, Moran-Garrido M, Perfetto S, Lin WZ, Ryoo SW et al. Journal of Alzheimer's disease : JAD (2026)
[12]
A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease. — Kanwal A, Kerman BE, Wang S, Camey K, Li B, Flores-Aguilar L et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2026)
[13]
Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease. — Elia A, Parodi-Rullan R, Vazquez-Torres R, Carey A, Zhao H, Javadov S et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
[14]
Exploring the intersection of Alzheimer's disease and comorbidities: a review of the interplay between multiple chronic conditions. — Khan S, Imam A, Singh S, Ahmed A, Hassan MI, Shahid M et al. Biochimica et biophysica acta. Molecular basis of disease (2026)
[15]
Limited evidence for heart rate variability as a predictor of cognitive and pathophysiological brain markers. — Marcolini S, Mondragón JD, van Roon AM, Tegegne BS, Riese H, Vliegenthart R et al. Journal of Alzheimer's disease : JAD (2026)
[16]
Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory. — Anwer M, Poliakova T, Albanus RD, Bhuiyan MIH, Brickman AM, Chaudhuri S et al. Mammalian genome : official journal of the International Mammalian Genome Society (2026)
[17]
Accelerated MRI Sequences for Intracranial Hemorrhage Screening. — Loftus JR, McClelland AC, Hsu K, Nayak GK, Bruno M, Jachung R et al. Investigative radiology (2026)
[18]
White matter hyperintensity regression: Fact or artifact? — Bahrani AA, Nelson PT, Abner EL, Powell DK, Norris CM, Coskun EP et al. Neurobiology of aging (2026)
[19]
Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling. — Wang J, Zhang Y, Wu H, Yu S, Cai X, Zhang Y et al. Chinese journal of natural medicines (2026)
[20]
Association of LDL cargo proteins with white matter hyperintensity volume in older adults from the atherosclerosis risk in communities study. — An B, Auger SA, Lutsey PL, Mielke MM, Yu F, Hoogeveen RC et al. Journal of Alzheimer's disease : JAD (2026)
[21]
Sialylation patterns in cerebral amyloid angiopathy. — Fastenau C, Crisp R, Keating M, Ochoa E, Richardson TE, Flanagan ME et al. Brain pathology (Zurich, Switzerland) (2026)
[22]
Hypertension as a Major Risk Factor in Alzheimer's Disease: Mechanisms, Interactions and Therapeutic Perspectives. — Jiang E, Ullah S, Waheed I, Han J, Zhang X Clinical interventions in aging (2026)
[23]
Characterizing Alzheimer's Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record-Based Data. — Jafari EA, Alshahawey M, Zaman MA, Smith SM, Gong Y, Smith GE et al. Clinical pharmacology and therapeutics (2026)
[24]
Amyloid beta 42 disrupts cardiac function in Alzheimer's disease mice via SLC31A1 upregulation-mediated cuproptosis. — Xiong W, Luo Z, Wang H, Su Q, Wang H, Xu J et al. Basic research in cardiology (2026)
[25]
Class-Specific Antihypertensives and Alzheimer's Disease: Genotype- and Hypertension-Stratified Analysis. — Yang D, Wei R, Zhu J, Chen J, Wang S, Cai H et al. Molecular neurobiology (2026)
[26]
The causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic review. — Parker S, James AF, Mastitskaya S The Journal of physiology (2026)
[27]
The brain neurovascular epigenome and its association with dementia. — Ziegler KC, Askarova A, Gergian C, Yaa RM, van Dalen JD, Transfeld JL et al. Neuron (2026)
[28]
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. — Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[29]
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. — Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[30]
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. — Dickerson BC, Atri A, Clevenger C, Karlawish J, Knopman D, Lin PJ et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[31]
Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. — Suárez-Calvet M, Abdelnour C, Alcolea D, Mendióroz-Iriarte M, Balasa M, Morenas-Rodríguez E et al. Neurologia (2025)
[32]
Integrating home-based video teleneuropsychology into neurology clinical practice: Utility in patients with suspected typical or atypical Alzheimer's disease presentations. — Bettcher BM, Gunn-Sandell LB, Lopez-Esquibel N, Carlson NE, Krupa JR, Lum HD et al. The Clinical neuropsychologist (2025)
[33]
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis. — Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N Ageing research reviews (2025)
[34]
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. — Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[35]
Practical brain MRI guidelines for anti-Aβ antibody treatment in early symptomatic Alzheimer's disease. — Kakeda S, Miki Y, Kudo K, Mori H, Tokumaru AM, Abe O et al. Japanese journal of radiology (2025)
[36]
Trends in the Prevalence and Development of Alzheimer's Disease Among the Elderly Chinese Population: A Systematic Review. — Han GZ, Liang ZH, Guo LY, Liu MM Revista de neurologia (2025)
[37]
Optimizing exercise dosage for executive function in alzheimer's disease: A Bayesian dose-response meta-analysis of randomized trials. — Sui S, Wang M Archives of gerontology and geriatrics (2025)
[38]
Bibliometric analysis: A few suggestions (Part Two). — Abdelwahab SI, Taha MME, Farasani A, Abdullah SM, Moshi JM, Alshahrani AF et al. Current problems in cardiology (2025)
[39]
Monoclonal Antibody Therapies in Alzheimer's Disease: A Guide for Emergency Physicians. — Wrigley S, Huynh ALH, Amadoru S, Zeimer H, Tan I, Woodward M et al. Emergency medicine Australasia : EMA (2025)
[40]
Anti-Amyloid Therapies for Alzheimer's Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician. — Rech MA, Carpenter CR, Aggarwal NT, Hwang U Annals of emergency medicine (2025)
[41]
Increasing Representation/Inclusivity of Older Adults and Investigators From Minoritized Groups in Aging Research. — Harden JT, Heyn PC, Hill CV, Oh ES, Perez GA The Gerontologist (2025)
[42]
Inspiring Undergraduate Student Training in Alzheimer's Research (USTAR): Training the Next Generation of Aging Scientists. — Casten R, Kelley M, Lawal H, Lopez BL, Parks S, Perchiniak E et al. Journal of the American Geriatrics Society (2025)
[43]
A dual approach to addressing gaps in scholar diversity in aging research. — Austin ME, Ingram LA, McCollum Q, Levkoff SE, Friedman DB Gerontology & geriatrics education (2025)
[44]
A joint learning framework for analyzing data from national geriatric centralized networks: A new toolbox deciphering real-world complexity. — Shen B, Zhang Y, Travison TG, Shardell M, McCoy RG, Saegusa T et al. Journal of biomedical informatics (2025)
[45]
Commonly prescribed multi-medication therapies exert sex-specific effects on Alzheimer's disease pathology and metabolomic profiles in App — Eroli F, Johnell K, Acararicin Z, Tsagkogianni C, Zerial S, Lancia S et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[46]
Impact of Polypharmacy on Symptoms and Health Outcomes in Older Adults With and Without Alzheimer's Disease and Related Dementias. — Coates MC, McClure LA, Vader D, Finley M, Sefcik JS, Gitlin LN et al. Biological research for nursing (2025)
[47]
A matched case-control study on polypharmacy and co-medications one year before drug treatment for Alzheimer's disease. — Alghamdi A, de Vos S, Bos JH, Schuiling-Veninga CC, van Munster BC, Mubarik S et al. Journal of Alzheimer's disease : JAD (2025)
[48]
A systems immunology analysis of Alzheimer's disease reveals an age- and environmental exposure-independent disturbance in B cell maturation. — Humblet-Baron S, Feng Y, Veiga R, Neumann J, Prezzemolo T, Pasciuto E et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2025)
[49]
Immediate and long-term effects of transcranial direct current stimulation on pain relief in older adults with Alzheimer's disease and related dementias: A pilot study. — Lee C, Park J, Fain M, Galvin JE, Park L, Ahn H Geriatric nursing (New York, N.Y.) (2025)
[50]
Unlocking the Vitamin Puzzle: Investigating Levels in People With Alzheimer's Disease Versus Healthy Controls Through Systematic Review and Network Meta-Analysis. — Marwaha S, Agarwal R, Tripathi M, Tripathi S Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2025)
[51]
Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database. — Han W, Morris R, Bu K, Zhu T, Huang H, Cheng F Canadian journal of physiology and pharmacology (2025)
[52]
Unveiling Aducanumab's safety profile: A comprehensive pharmacovigilance analysis. — Ji H, Zhao Z, Zhao C PloS one (2025)
[53]
Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. — Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X et al. Alzheimer's research & therapy (2025)
[54]
Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system. — Li J, Zhang F, Eisel UL Journal of Alzheimer's disease : JAD (2025)
[55]
Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data. — Ge W, Yan Y, Hu Y, Lin S, Mao P Journal of Alzheimer's disease : JAD (2025)
[56]
Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer's Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System. — Zhou J, Wei Z, Huang W, Liu M, Wu X The Annals of pharmacotherapy (2025)
[57]
Alterations of Apolipoprotein A1, E, and J Genes in the Frontal Cortex in an Ischemic Model of Alzheimer's Disease with 2-Year Survival. — Pluta R, Ułamek-Kozioł M, Kocki J, Bogucka-Kocka A, Bogucki J, Czuczwar SJ International journal of molecular sciences (2025)
[58]
Neural circuit mechanisms underlying aberrantly prolonged functional hyperemia in young Alzheimer's disease mice. — Kim TA, Cruz G, Syty MD, Wang F, Wang X, Duan A et al. Molecular psychiatry (2025)
[59]
Prevalence and associations of cerebral microbleeds in an Australian Memory clinic cohort. — Wrigley S, Cody R, Amadoru S, Huynh A, Galante O, Mandrawa C et al. Internal medicine journal (2025)
[60]
Cerebral hypoperfusion reduces tau accumulation. — Gheni G, Shinohara M, Masuda-Suzukake M, Shindo A, Watanabe A, Kawai K et al. Annals of clinical and translational neurology (2025)
[61]
Hypotension with neurovascular changes and cognitive dysfunction: An epidemiological, pathobiological, and treatment review. — Cheng Y, Lin L, Huang P, Zhang J, Wang Y, Pan X Chinese medical journal (2025)
[62]
APOE Lipoprotein Particles: Pathophysiology, Therapy, and the Crosstalk in Alzheimer's Disease and Cardiovascular Disease. — Liu C, Liu J, Wang YY, Xu SF, Yu LM Molecular neurobiology (2025)
[63]
Identification of Alzheimer's disease and vascular dementia based on a Deep Forest and near-infrared spectroscopy analysis method. — Huang W, Zeng R, Li Y, Hua Y, Liu L, Chen M et al. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy (2025)
[64]
Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management. — Wei X, Li L, Zhao G, Luan Y, Wang Q, Ning W Clinical and experimental hypertension (New York, N.Y. : 1993) (2025)
[65]
The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update. — Yasmin S, Ashique S, Taj T, Garg A, Das J, Shorog E et al. Brain research (2025)
[66]
Using principal component analysis to determine which vestibular stimuli provide best biomarkers for separating Alzheimer's from mixed Alzheimer's disease. — Marzban S, Dastgheib Z, Lithgow B, Moussavi Z Medical & biological engineering & computing (2025)
[67]
Efficient Seeding of Cerebral Vascular Aβ-Amyloidosis by Recombinant AβM1-42 Amyloid Fibrils. — Parvin F, Larsson JNK, Jackson WS, Nyström S, Hammarström P Journal of molecular biology (2025)
[68]
Autophagy Regulation Attenuates Neuroinflammation and Cognitive Decline in an Alzheimer's Disease Mouse Model with Chronic Cerebral Hypoperfusion. — Yang Q, Yang C, Lv H, Zheng X, Mao S, Liu N et al. Inflammation (2025)
[69]
Apolipoprotein ( — Pluta R, Kocki J, Bogucki J, Bogucka-Kocka A, Czuczwar SJ Journal of Alzheimer's disease : JAD (2025)
[70]
Role of Cardiovascular Risk in Associations of Brain-Derived Neurotrophic Factor with Longitudinal Brain and Cognitive Trajectories in Older Adults. — Shearon J, Jackson J, Head D Experimental aging research (2025)
[71]
Distinguishing Alzheimer's disease from other dementias using pattern profile analysis in the Meyers Neuropsychological Battery: An exploratory study. — Piccolino AL, Piccolino AR, Piccolino SG Applied neuropsychology. Adult (2025)
[72]
Iatrogenic cerebral amyloid angiopathy and Alzheimer's disease co-pathology. — Hernández-Fernández F, Martínez-Fernández I, Barbella-Aponte R, Vilar IF, Ayo-Martín O, García-García J et al. Annals of clinical and translational neurology (2025)
[73]
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure. — Reimers-Wessberg M, Xu H, Fastbom J, Seiger Å, Eriksdotter M European heart journal. Cardiovascular pharmacotherapy (2025)
[74]
Sex-specific association of comorbid heart failure on mortality after Alzheimer's disease diagnosis in older adults aged 75 years and above: A health insurance claims data analysis in Japan. — Matsunaga M, Tanihara S, He Y, Yatsuya H, Ota A Journal of Alzheimer's disease : JAD (2025)
[75]
Incidence and prevalence of Alzheimer's disease in China: a systematic review and meta-analysis. — Ji Q, Chen J, Li Y, Tao E, Zhan Y European journal of epidemiology (2024)
[76]
Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis. — Nijakowski K, Owecki W, Jankowski J, Surdacka A International journal of molecular sciences (2024)
[77]
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. — Terao I, Kodama W Ageing research reviews (2024)
[78]
Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. — Gao Y, Liu Y, Li Y Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2024)
[79]
Comparison of Cognitive Intervention Strategies for Individuals With Alzheimer's Disease: A Systematic Review and Network Meta-analysis. — Xiang C, Zhang Y Neuropsychology review (2024)
[80]
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. — Avgerinos KI, Manolopoulos A, Ferrucci L, Kapogiannis D Scientific reports (2024)
[81]
Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. — Terao I, Kodama W Journal of Alzheimer's disease : JAD (2024)
[82]
The safety and effectiveness of 40 Hz γ-tACS in Alzheimer's disease: A meta-analysis. — Zhang X, Lv R, Sun Y, Liu TC Journal of Alzheimer's disease : JAD (2024)
[83]
A Meta-Analysis on Presynaptic Changes in Alzheimer's Disease. — Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G Journal of Alzheimer's disease : JAD (2024)
[84]
Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society. — Cheng YW, Lin YJ, Lin YS, Hong WP, Kuan YC, Wu KY et al. Journal of the Formosan Medical Association = Taiwan yi zhi (2024)
[85]
Predictors for survival in patients with Alzheimer's disease: a large comprehensive meta-analysis. — Zheng X, Wang S, Huang J, Li C, Shang H Translational psychiatry (2024)
[86]
Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-β and Phosphorylated Tau Proteins. — García-Carlos CA, Basurto-Islas G, Perry G, Mondragón-Rodríguez S Journal of Alzheimer's disease : JAD (2024)
[87]
Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis. — McLaughlin J, Scotton WJ, Ryan NS, Hardy JA, Shoai M Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
[88]
Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis. — Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q European neurology (2024)
[89]
Lipid drops in on Alzheimer's disease. — Baek AE Science signaling (2024)
[90]
Special Issue "Pathophysiology and Treatment of Alzheimer's Disease". — Fessel J International journal of molecular sciences (2024)
[91]
They Are Here: Anti-Amyloid Therapies to Treat Dementia. — Antimisiaris D The Senior care pharmacist (2024)
[92]
Preprint on Alzheimer's drug deaths ignites author dispute. — Couzin-Frankel J Science (New York, N.Y.) (2024)
[93]
Hunt for infectious causes of Alzheimer's gains momentum. — Couzin-Frankel J Science (New York, N.Y.) (2024)
[94]
Geroscience and the Fight Against Alzheimer's Disease: Between Myth and Reality. — Boccardi V, Ruggiero C, Cecchetti R, Mecocci P Journal of Alzheimer's disease : JAD (2024)
[95]
Intentional Strategic Changes in the National Institute on Aging's RCMAR Program: Broadening its Scope and Reach to Strengthen its Impact. — Gerald MS, Major L The Gerontologist (2024)
[96]
Advancing Diversity in Aging and Alzheimer's Disease Research and Clinical Care: Lessons Learned from Educational and Career Trajectories of Recent Mentorship Program Graduates. — Thompson S, Trinidad D, Woo E, Edland S, Marquez B International journal of aging & human development (2024)
[97]
An environmental scan of aging-related micro-credentials: Implications for gerontology and gerontologists. — Guest MA, Clark-Shirley L, Hancock C, Newsham TMK, Nikzad-Terhune K, Jenkins K Gerontology & geriatrics education (2024)
[98]
Implementation of equine-assisted intervention for older adults with Alzheimer's disease residing in a nursing home: Brakes and levers. — Badin L, Bailly N, Pennequin V International journal of older people nursing (2024)
[99]
Artificial Intelligence and Technology Collaboratories: Innovating aging research and Alzheimer's care. — Abadir P, Oh E, Chellappa R, Choudhry N, Demiris G, Ganesan D et al. Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
[100]
The relationship between polypharmacy and physical performance in patients with early-stage Alzheimer's disease. — Akkan Suzan A, Ozen Barut B Current medical research and opinion (2024)

Share:Twitter Reddit LinkedIn